University of Washington, Seattle, WA, USA; World Health Organization, Department of Immunization, Vaccines and Biologicals (IVB), Geneva, Switzerland.
World Health Organization, Division of Data, Analytics and Delivery for Impact (DDI), Geneva, Switzerland.
Vaccine. 2024 Apr 8;42 Suppl 1:S28-S37. doi: 10.1016/j.vaccine.2023.07.033. Epub 2023 Aug 1.
The Immunization Agenda 2030 (IA2030) Impact Goal 1.1. aims to reduce the number of future deaths averted through immunization in the next decade. To estimate the potential impact of the aspirational coverage targets for IA2030, we developed an analytical framework and estimated the number of deaths averted due to an ambitious vaccination coverage scenario from 2021 to 2030 in 194 countries.
A demographic model was used to determine annual age-specific mortality estimates associated with vaccine coverage rates. For ten pathogens (Hepatitis B virus, Haemophilus influenzae type B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, Streptococcus pneumoniae, rotavirus, rubella, yellow fever), we derived single measures of country-, age-, and pathogen-specific relative risk of deaths conditional upon coverage rates, leveraging the data from 18 modeling groups as part of the Vaccine Impact Model Consortium (VIMC) for 110 countries. We used a logistic regression model to extrapolate the relative risk estimates to countries that were not modeled by VIMC. For four pathogens (diphtheria, tetanus, pertussis and tuberculosis), we used estimates from the Global Burden of Disease 2019 study and existing literature on vaccine efficacy. A future scenario defining years of vaccine introduction and scale-up needed to reach aspirational targets was developed as an input to estimate the long-term impact of vaccination taking place from 2021 to 2030.
Overall, an estimated 51.5 million (95 % CI: 44.0-63.2) deaths are expected to be averted due to vaccinations administered between the years 2021 and 2030. With immunization coverage projected to increase over 2021-2030 an average of 5.2 million per year (4.4-6.3) deaths will be averted annually, with 4.4 million (3.9-5.1) deaths be averted for the year 2021, gradually rising to 5.8 million (4.9-7.5) deaths averted in 2030. The largest proportion of deaths is attributed to Measles and Hepatitis B accounting for 18.8 million (17.8-20.0) and 14.0 million (11.5-16.9) of total deaths averted respectively.
The results from this global analysis demonstrate the substantial potential mortality reductions achievable if the IA2030 targets are met by 2030. Deaths caused by vaccine preventable diseases disproportionately affect LMICs in the African region.
免疫议程 2030(IA2030)的影响目标 1.1. 旨在减少未来十年通过免疫接种避免的死亡人数。为了估计 IA2030 的理想覆盖目标的潜在影响,我们开发了一个分析框架,并估计了 194 个国家 2021 年至 2030 年期间,由于雄心勃勃的疫苗接种覆盖率情景而避免的死亡人数。
使用人口统计模型确定与疫苗覆盖率相关的每年特定年龄的死亡率估计值。对于十种病原体(乙型肝炎病毒、乙型流感嗜血杆菌、人乳头瘤病毒、日本脑炎、麻疹、脑膜炎奈瑟菌 A 群、肺炎链球菌、轮状病毒、风疹、黄热病),我们根据来自 18 个建模组的数据,针对国家、年龄和病原体特异性的死亡率条件,确定了死亡率的单一衡量标准,这些数据是疫苗影响模型联盟(VIMC)为 110 个国家提供的。我们使用逻辑回归模型将相对风险估计值外推到 VIMC 未建模的国家。对于四种病原体(白喉、破伤风、百日咳和结核病),我们使用了 2019 年全球疾病负担研究和疫苗功效现有文献中的估计值。开发了一个定义实现理想目标所需的疫苗引入和扩大规模的未来情景,作为估计从 2021 年至 2030 年进行疫苗接种的长期影响的输入。
总体而言,预计 2021 年至 2030 年期间接种疫苗将避免 5150 万人(95%CI:4400-6320)死亡。预计免疫覆盖率将在 2021-2030 年期间每年平均增加 520 万人(440-630),每年将避免 440 万人(390-510)死亡,2021 年将避免 440 万人(390-510)死亡,到 2030 年将逐渐上升至 580 万人(490-750)死亡。大部分死亡归因于麻疹和乙型肝炎,分别占避免的总死亡人数的 1880 万人(1780-2000)和 1400 万人(1150-1690)。
这项全球分析的结果表明,如果到 2030 年实现 IA2030 目标,将可实现大量的潜在死亡率降低。疫苗可预防疾病造成的死亡不成比例地影响非洲区域的中低收入国家。